15-Year Analysis Shows Decrease in Ovarian Cancer Incidence, Incidence-Based Mortality
February 9th 2024The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.
Read More
CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds
February 2nd 2024In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
Cytomegalovirus Common in Patients With Ovarian Cancer, May Contribute to Cognitive Impairment
November 19th 2023Researchers noted that it remains unclear whether cytomegalovirus (CMV) infection is a specific cause of worsened cancer-related cognitive impairment (CRCI), or if it is a biomarker for immune suppression.
Read More
Olaparib Does Not Improve OS vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer
November 17th 2023The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival (OS) benefit compared with standard of care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.
Read More
Multidisciplinary Surgical Team Approach Improves OS in Ovarian Cancer
November 1st 2023After implementing a multidisciplinary surgical approach, researchers found that use of the new approach, residual disease, and age were all independent predictors of overall and progression-free survival for patients with ovarian cancer.
Read More
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
October 31st 2023The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Read More
Triplet Maintenance Therapy Effective in Platinum-Sensitive Recurrent Ovarian Cancer
October 31st 2023Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
Read More
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
FDA Grants Fast Track Designation to IDE161 for BRCA+, Platinum-Resistant Advanced Ovarian Cancer
September 30th 2023The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and poly-ADP ribose polymerase, or PARP, inhibitor therapies.
Read More
Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer
September 12th 2023Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
Read More
TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer
September 9th 2023The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.
Read More
Study Highlights Factors Linked to ED Readmission Following Ovarian Carcinoma Surgery
September 6th 2023Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.
Read More